NVAX - Novavax Inc Stock Price, Fair Value and News

13.01USD-1.39 (-9.65%)Market Closed

Market Summary

USD13.01-1.39

Market Closed

-9.65%

NVAX Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

NVAX Stock Price

View Fullscreen

NVAX RSI Chart

NVAX Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-4.58

Price/Sales (Trailing)

1.83

EV/EBITDA

-3.95

Price/Free Cashflow

-3.87

NVAX Price/Sales (Trailing)

NVAX Profitability

Operating Margin

62.99%

EBT Margin

-39.69%

Return on Equity

45.98%

Return on Assets

-29.46%

Free Cashflow Yield

-25.84%

NVAX Fundamentals

NVAX Revenue

Revenue (TTM)

996.6M

Rev. Growth (Yr)

15.94%

Rev. Growth (Qtr)

-67.79%

NVAX Earnings

Earnings (TTM)

-398.7M

Earnings Growth (Yr)

49.8%

Earnings Growth (Qtr)

17.29%

Breaking Down NVAX Revenue

Last 7 days

46.5%

Last 30 days

234.5%

Last 90 days

212.7%

Trailing 12 Months

75.3%

How does NVAX drawdown profile look like?

NVAX Financial Health

Current Ratio

0.9

NVAX Investor Care

Shares Dilution (1Y)

62.68%

Diluted EPS (TTM)

-3.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	996.6M	0	0	0
2023	1.4B	1.6B	1.0B	983.7M
2022	1.4B	1.3B	1.8B	2.0B
2021	919.5M	1.2B	1.2B	1.1B
2020	18.1M	50.2M	204.8M	475.6M
2019	28.6M	21.2M	16.0M	18.7M
2018	35.1M	39.2M	38.6M	34.3M
2017	16.8M	21.0M	26.2M	31.2M
2016	30.6M	19.1M	15.8M	15.4M
2015	33.1M	38.8M	37.1M	36.3M
2014	24.5M	29.3M	32.7M	30.7M
2013	21.3M	17.7M	16.7M	20.9M
2012	18.5M	22.6M	23.4M	22.1M
2011	2.2M	4.1M	8.9M	14.7M
2010	0	331.0K	337.0K	343.0K
2009	0	0	0	325.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Novavax Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 10, 2024	dubovsky filip	sold (taxes)	-14,153	5.45	-2,597	president, r&d
Mar 10, 2024	kelly james patrick	sold (taxes)	-12,131	5.45	-2,226	evp, cfo and treasurer
Mar 10, 2024	trizzino john	sold (taxes)	-12,131	5.45	-2,226	president and coo
Mar 10, 2024	dubovsky filip	acquired	-	-	5,376	president, r&d
Mar 10, 2024	kelly james patrick	acquired	-	-	4,608	evp, cfo and treasurer
Mar 10, 2024	trizzino john	acquired	-	-	4,608	president and coo
Mar 07, 2024	kelly james patrick	sold (taxes)	-33,127	5.61	-5,905	evp, cfo and treasurer
Mar 07, 2024	dubovsky filip	sold (taxes)	-52,689	5.61	-9,392	president, r&d
Mar 07, 2024	dubovsky filip	acquired	-	-	19,444	president, r&d
Mar 07, 2024	trizzino john	sold (taxes)	-78,287	5.61	-13,955	evp, cco and cbo

Which funds bought or sold NVAX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	11.34	50,405	513,903	-%
May 16, 2024	COMERICA BANK	sold off	-100	-1,560	-	-%
May 16, 2024	Global Financial Private Client, LLC	unchanged	-	-	5.00	-%
May 16, 2024	AVENIR CORP	sold off	-100	-136,608	-	-%
May 16, 2024	Tidal Investments LLC	new	-	172,156	172,156	-%
May 16, 2024	Murchinson Ltd.	sold off	-100	-480,000	-	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-91.64	-4,824,990	438,231	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	3,735,000	3,735,000	-%
May 15, 2024	FARALLON CAPITAL MANAGEMENT LLC	new	-	5,406,180	5,406,180	0.02%
May 15, 2024	CITADEL ADVISORS LLC	new	-	1,389,310	1,389,310	-%

Are Funds Buying or Selling NVAX?

Are funds buying NVAX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVAX

No. of Funds

Unveiling Novavax Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 07, 2024	shah capital management	7.6%	10,700,794	SC 13D/A
Apr 15, 2024	shah capital management	6.66%	9,326,176	SC 13D
Apr 15, 2024	shah capital management	6.66%	9,326,176	SC 13D/A
Mar 07, 2024	morgan stanley	1.8%	2,454,328	SC 13G/A
Feb 13, 2024	vanguard group inc	12.26%	14,560,054	SC 13G/A
Feb 09, 2024	morgan stanley	6.2%	7,308,033	SC 13G
Jan 26, 2024	blackrock inc.	7.1%	8,436,179	SC 13G/A
Jan 25, 2024	state street corp	14.12%	16,775,875	SC 13G/A
Aug 18, 2023	sk bioscience co., ltd.	6.4%	6,500,000	SC 13G
May 10, 2023	state street corp	12.11%	10,452,512	SC 13G/A

Recent SEC filings of Novavax Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 14, 2024	144	Notice of Insider Sale Intent
May 13, 2024	8-K	Current Report
May 13, 2024	DFAN14A	DFAN14A
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
May 08, 2024	DFAN14A	DFAN14A
May 07, 2024	SC 13D/A	13D - Major Acquisition
May 07, 2024	DFAN14A	DFAN14A
May 06, 2024	DFAN14A	DFAN14A

Peers (Alternatives to Novavax Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Novavax Inc News

Latest updates

Novavax Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-67.8%	93,855,000	291,342,000	186,986,000	424,426,000	80,951,000	357,399,000	734,577,000	185,925,000	703,971,000	222,200,000	178,844,000	298,017,000	447,229,000	279,659,000	157,024,000	35,538,000	3,377,000	8,816,000	2,507,000	3,357,000	3,982,000
Cost Of Revenue	-61.8%	59,209,000	154,976,000	98,929,000	55,777,000	34,086,000	181,765,000	434,593,000	271,077,000	15,204,000	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-49.7%	238,686,000	474,910,000	312,618,000	368,969,000	393,719,000	601,278,000	861,766,000	668,885,000	494,679,000	1,047,171,000	485,988,000	643,846,000	655,861,000	462,512,000	350,966,000	52,565,000	26,274,000	37,521,000	17,494,000	40,023,000	44,205,000
S&GA Expenses	-100.0%	-	155,237,000	107,460,000	93,717,000	112,532,000	161,663,000	122,876,000	108,160,000	95,992,000	84,214,000	77,793,000	73,161,000	63,190,000	61,313,000	56,879,000	17,719,000	9,379,000	8,180,500	7,899,000	9,606,000	8,732,000
R&D Expenses	-43.7%	92,679,000	164,697,000	106,229,000	219,475,000	247,101,000	257,850,000	304,297,000	289,648,000	383,483,000	962,957,000	408,195,000	570,685,000	592,671,000	401,199,000	294,087,000	34,846,000	16,895,000	29,340,500	18,611,000	30,417,000	35,473,000
EBITDA Margin	31.7%	-0.34	-0.50	-0.47	-0.33	-0.81	-0.31	-0.68	-1.09	-0.89	-1.47	-0.86	-0.78	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.1%	4,111,000	4,117,000	2,859,000	3,124,000	4,316,000	4,601,000	4,169,000	6,234,000	4,876,000	5,138,000	5,182,000	5,968,000	4,839,000	3,879,000	4,460,000	3,403,000	3,403,000	3,403,000	3,403,000	3,403,000	3,403,000
Income Taxes	34.0%	2,262,000	1,688,000	-697,000	-143,000	1,183,000	-2,260,000	2,472,000	1,418,000	2,662,000	16,609,000	6,041,000	3,548,000	3,017,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	17.8%	-145,288,000	-176,701,000	-131,473,000	57,865,000	-292,722,000	-184,509,000	-166,141,000	-509,067,000	206,070,000	-829,675,000	-316,390,000	-348,769,000	-219,702,000	-177,564,000	-197,310,000	-17,521,000	-	-	-	-	-
EBT Margin	28.1%	-0.40	-0.55	-0.52	-0.37	-0.85	-0.33	-0.70	-1.12	-0.92	-1.50	-0.88	-0.80	-	-	-	-	-	-	-	-	-
Net Income	17.3%	-147,550,000	-178,389,000	-130,776,000	58,008,000	-293,905,000	-182,249,000	-168,613,000	-510,485,000	203,408,000	-846,284,000	-322,431,000	-352,317,000	-222,719,000	-177,564,000	-197,310,000	-17,521,000	-25,864,000	-31,830,000	-18,043,000	-39,603,000	-43,218,000
Net Income Margin	27.8%	-0.40	-0.55	-0.52	-0.37	-0.85	-0.33	-0.72	-1.14	-0.94	-1.52	-0.89	-0.80	-	-	-	-	-	-	-	-	-
Free Cashflow	52.7%	-83,555,000	-176,767,000	-61,680,000	-193,949,000	-347,604,000	-139,827,000	-60,719,000	-184,610,333	-102,217,333	-356,115,333	-155,850,333	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-24.7%	1,354	1,797	1,657	1,685	1,543	2,259	2,267	2,623	2,835	2,577	2,566	2,750	2,608	1,582	944	932	328	173	165	189	221
Current Assets	-36.4%	727	1,144	1,007	1,128	971	1,703	1,760	2,136	2,347	2,155	2,174	2,355	2,247	1,248	671	636	255	97.00	89.00	110	123
Cash Equivalents	-12.8%	496	569	651	506	625	1,337	1,293	1,388	1,584	1,515	1,947	2,123	2,029	649	402	532	187	82.00	76.00	78.00	106
Inventory	-62.2%	16.00	42.00	70.00	23.00	34.00	37.00	82.00	256	107	9.00	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.8%	291	306	301	300	307	294	256	255	247	226	215	213	192	180	132	115	11.00	11.00	12.00	13.00	27.00
Goodwill	-3.4%	123	127	124	128	130	126	118	123	131	131	132	134	131	135	127	119	50.00	51.00	50.00	51.00	51.00
Liabilities	-11.7%	2,221	2,514	2,336	2,440	2,438	2,893	2,833	3,040	2,770	2,928	2,105	2,004	1,569	955	638	548	352	359	355	375	372
Current Liabilities	-50.8%	804	1,635	1,469	1,596	1,919	2,460	1,668	2,156	2,261	2,390	1,753	1,652	1,209	580	239	213	19.00	26.00	22.00	41.00	31.00
Shareholder's Equity	-20.9%	-867	-716	-	-	-895	-634	-	-	65.00	-	461	746	1,039	627	106	185	-	-	-	-	-
Retained Earnings	-3.1%	-4,968	-4,820	-4,642	-4,511	-4,569	-4,275	-4,093	-3,925	-3,414	-3,617	-2,771	-2,449	-2,096	-1,874	-1,696	-1,499	-1,457	-1,431	-1,399	-1,381	-1,342
Additional Paid-In Capital	0.3%	4,205	4,192	4,067	3,856	3,768	3,738	3,641	3,605	3,566	3,352	3,311	3,237	3,180	2,535	1,849	1,699	1,450	1,261	1,226	1,211	1,202
Shares Outstanding	0.6%	140	140	119	94.00	86.00	86.00	78.00	78.00	76.00	74.00	74.00	74.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	699	-	-	-	4,010	-	-	-	15,697	-	-	-	5,079	-	-	-	138	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	52.7%	-83.55	-176	-39.67	-171	-325	-117	-38.71	-170	-88.51	-342	-142	144	663	-128	-6.50	116	-23.11	-23.74	-32.26	-30.01	-50.61
Share Based Compensation	-26.2%	12.00	16.00	21.00	20.00	29.00	28.00	32.00	38.00	33.00	32.00	45.00	53.00	53.00	50.00	66.00	8.00	4.00	4.00	3.00	5.00	6.00
Cashflow From Investing	20.1%	-7.25	-9.08	-18.39	-7.78	-23.56	-22.06	-29.52	-24.58	-16.83	-16.36	-12.19	-12.90	142	-31.12	-100	-188	-57.73	-0.22	18.00	2.00	19.00
Cashflow From Financing	-94.1%	6.00	100	197	61.00	-354	191	-30.98	5.00	160	-60.71	-15.72	-38.84	577	405	-22.39	417	186	30.00	12.00	0.00	56.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NVAX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenues	$ 93,855	$ 80,951
Expenses:
Cost of sales	59,209	34,086
Research and development	92,679	247,101
Selling, general, and administrative	86,798	112,532
Total expenses	238,686	393,719
Loss from operations	(144,831)	(312,768)
Other income (expense):
Interest expense	(4,111)	(4,316)
Other income	3,654	24,362
Loss before income taxes	(145,288)	(292,722)
Income tax expense	2,262	1,183
Net loss	$ (147,550)	$ (293,905)
Net loss per share:
Basic (in usd per share)	$ (1.05)	$ (3.41)
Diluted (in usd per share)	$ (1.05)	$ (3.41)
Weighted average number of common shares outstanding:
Basic (in shares)	139,916	86,158
Diluted (in shares)	139,916	86,158
Product sales
Revenue:
Revenues	$ 82,324	$ (7,457)
Grants
Revenue:
Revenues	0	87,379
Royalties and other
Revenue:
Revenues	$ 11,531	$ 1,029

NVAX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 480,586	$ 568,505
Restricted cash	10,455	10,424
Accounts receivable	21,380	297,240
Inventory	15,778	41,696
Prepaid expenses and other current assets	198,921	226,023
Total current assets	727,120	1,143,888
Property and equipment, net	291,093	305,771
Right of use asset, net	181,175	185,218
Goodwill	123,179	127,454
Other non-current assets	30,967	35,159
Total assets	1,353,534	1,797,490
Current liabilities:
Accounts payable	57,724	132,610
Accrued expenses	257,365	394,668
Deferred revenue	240,900	241,310
Current portion of finance lease liabilities	6,291	5,142
Other current liabilities	242,102	861,408
Total current liabilities	804,382	1,635,138
Deferred revenue	841,473	622,210
Convertible notes payable	168,432	168,016
Non-current finance lease liabilities	54,609	55,923
Other non-current liabilities	351,722	33,130
Total liabilities	2,220,618	2,514,417
Commitments and contingencies (Note 13)
Preferred stock, $0.01 par value, 2,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Stockholders' deficit:
Common stock, $0.01 par value, 600,000,000 shares authorized at March 31, 2024 and December 31, 2023; 141,700,972 shares issued and 140,373,255 shares outstanding at March 31, 2024 and 140,506,093 shares issued and 139,505,770 shares outstanding at December 31, 2023	1,417	1,405
Additional paid-in capital	4,204,775	4,192,164
Accumulated deficit	(4,968,501)	(4,820,951)
Treasury stock, cost basis, 1,327,717 shares at March 31, 2024 and 1,000,323 shares at December 31, 2023	(93,950)	(92,267)
Accumulated other comprehensive income (loss)	(10,825)	2,722
Total stockholders’ deficit	(867,084)	(716,927)
Total liabilities and stockholders’ deficit	$ 1,353,534	$ 1,797,490

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

CEO	Mr. John Charles Jacobs M.B.A.
WEBSITE	novavax.com
INDUSTRY	Biotechnology
EMPLOYEES	1992

Novavax Inc Frequently Asked Questions

What is the ticker symbol for Novavax Inc? What does NVAX stand for in stocks?

NVAX is the stock ticker symbol of Novavax Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novavax Inc (NVAX)?

As of Fri May 17 2024, market cap of Novavax Inc is 1.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVAX stock?

You can check NVAX's fair value in chart for subscribers.

What is the fair value of NVAX stock?

You can check NVAX's fair value in chart for subscribers. The fair value of Novavax Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Novavax Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Novavax Inc a good stock to buy?

The fair value guage provides a quick view whether NVAX is over valued or under valued. Whether Novavax Inc is cheap or expensive depends on the assumptions which impact Novavax Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVAX.

What is Novavax Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NVAX's PE ratio (Price to Earnings) is -4.58 and Price to Sales (PS) ratio is 1.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVAX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Novavax Inc's stock?

In the past 10 years, Novavax Inc has provided -0.174 (multiply by 100 for percentage) rate of return.